文献速递临床试验与 GCP流行病学与生物统计

MDMA与裸盖菇素干预临床试验注册方案与安全性数据报告及对应发表文献的一致性

Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin.
PubMed 文献 · J Clin Epidemiol · 2026-01-23

该横断面分析评估了截至2025年3月12日在ClinicalTrials.gov注册的所有MDMA或裸盖菇素临床试验(共336项),考察主要结局指标和入选标准随时间的变化及在发表文献中的披露情况,并比较已完成试验在文章与注册库中的不良事件报告。结果显示,17.6%的试验主要结局指标发生重大变更,28.6%的入选标准发生重大变更;72.0%的已完成试验未在注册库报告结果;仅29项同时有结果和发表文献的试验中3项不良事件报告完全一致。结论认为方案和不良事件报告的不一致损害了试验可信度和安全性评估,建议提高透明度和更严格遵守报告标准。

要点

  • 336项MDMA或裸盖菇素试验中,17.6%主要结局指标和28.6%入选标准发生重大变更,多发生在招募开始后。
  • 已完成试验中72.0%未在ClinicalTrials.gov报告结果,多数已发布结果超出FDAAA建议的1年报告窗口。
  • 29项同时有结果和发表文献的试验中仅3项不良事件报告完全一致,多数存在定性和定量差异。

核心结论

  • MDMA和裸盖菇素试验中方案和不良事件报告的不一致损害了试验可信度和安全性评估。
  • 作者建议提高透明度并更严格遵守报告标准,以确保可靠证据、保护参与者并维持利益相关者和公众信任。

研究设计与样本

  • 对截至2025年3月12日在ClinicalTrials.gov注册的所有MDMA或裸盖菇素临床试验进行横断面分析,共336项试验。
  • 评估每项试验主要结局指标和入选标准随时间的变化及在对应发表文献中的披露情况。
  • 对同时有已发布结果和发表文章的已完成试验,比较文章与ClinicalTrials.gov注册库中的不良事件报告。

主要发现

  • 336项试验中,17.6%的试验主要结局指标发生重大变更,28.6%的试验入选标准发生重大变更,多数变更发生在参与者招募开始后。
  • 已完成试验中,72.0%未在ClinicalTrials.gov报告结果,且多数已发布结果超出FDAAA建议的1年报告窗口。
  • 29项同时有已发布结果和发表文章的试验中,仅3项不良事件报告完全一致,多数存在定性和定量差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin are being investigated as potential treatments for psychiatric disorders and have received increasing regulatory and media attention due to the methodological complexities and societal context of psychedelic substances. Therefore, we assessed the consistency of protocol registration and adverse event (AE) reporting in clinical trials of MDMA and psilocybin. STUDY DESIGN AND SETTING: We conducted a cross-sectional analysis of all clinical trials on MDMA or psilocybin registered on ClinicalTrials.gov by March 12, 2025. For each trial, we assessed changes to primary outcome measures (POMs) and eligibility criteria over time and evaluated whether these changes were disclosed in corresponding publications. For completed trials with both posted results and published articles, we compared AE reporting between the article and the corresponding ClinicalTrials.gov registration. RESULTS: Out of 336 trials, major changes were recorded to POMs for 17.6% trials and to eligibility criteria for 28.6% trials, most of which occurred after participant recruitment began. Among completed trials, 72.0% did not report results on ClinicalTrials.gov, and most posted results exceeded the FDAAA-recommended 1-year reporting window. Only three of 29 trials with both posted results and publications showed full concordance in AE reporting, with most exhibiting both qualitative and quantitative discrepancies. CONCLUSION: Inconsistencies in protocol and AE reporting undermine the credibility and safety evaluation of MDMA and psilocybin trials. Greater transparency and stricter adherence to reporting standards are advised to ensure reliable evidence, protect participants, and maintain stakeholder and public trust.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Žuljević MF, Mijatović A, Orhanović R, et al. Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin. J Clin Epidemiol. 2026. PMID: 41581835. doi:10.1016/j.jclinepi.2026.112170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。